SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
11.49
-0.04 (-0.35%)
At close: Sep 18, 2026, 4:00 PM EDT
11.77
+0.28 (2.44%)
Pre-market: Sep 21, 2026, 4:42 AM EDT
SLS Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
2.32B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.00M | -6.60M | -86.84% |
| Dec 31, 2021 | 7.60M | 5.70M | 300.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| Aurinia Pharmaceuticals | 311.51M |
| Beam Therapeutics | 156.04M |
| Viridian Therapeutics | 71.13M |
| Nektar Therapeutics | 54.59M |
| Ocular Therapeutix | 52.06M |
| Generate Biomedicines | 26.48M |
SLS News
- 18 days ago - SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer - GlobeNewsWire
- 27 days ago - SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon - TipRanks
- 4 weeks ago - Moderna data bode well for Sellas into imminent readout, says Maxim - TheFly
- 4 weeks ago - Sellas Life Sciences price target raised to $35 from $25 at Alliance Global - TheFly
- 5 weeks ago - SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences Group Quarterly report: Q2 2026 - Filings
- 5 weeks ago - SELLAS Life Sciences Group Earnings release: Q2 2026 - Filings
- 2 months ago - Sellas Life Sciences rises 11.0% - TheFly